by The global Non-invasive Aesthetic Treatment market size is expected to be worth around US$ 150.0 billion by 2030, according to a new report by Vision Research Reports.
The global Non-invasive Aesthetic Treatment market size was valued at US$ 49.0 billion in 2020 and is anticipated to grow at a CAGR of 15.7% during forecast period 2021 to 2030.
Download Exclusive Sample of Report@ https://www.visionresearchreports.com/report/sample/39012
Table of Contents
Non-invasive Aesthetic Treatment Market Growth Factors
Growing focus on physical appearance among adults has led to an increased demand for non-invasive aesthetic treatment in recent years. Another key revenue-generating population to watch out for are the ones aged 50+ years and above. Women in this age group are opting for fillers and injectablesincluding the popular, Botox. According to the American Society for Aesthetic Plastic Surgery (ASAPS), in 2019, around 3.8 million minimally invasive cosmetic surgeries were carried out in the US within the age group of 55 and above. The COVID-19 pandemic has significantly affected the non-invasive aesthetic treatment market. The cosmetics industry relies on close physical contact with their clients, leaving it negatively affected. Practitioners have also raised concerns over the downturn in inpatient interest owing to a sharp cut in income level. The market for non-invasive aesthetic treatment is expected to witness a phase of short-term negative growth.
Non-invasive Aesthetic Treatment Market Report Coverage
| Report Scope | Details |
| Market Size | US$ 150.0 billion by 2030 |
| Growth Rate | CAGR of 15.7% From 2021 to 2030 |
| Base Year | 2021 |
| Forecast Period | 2021 to 2030 |
| Segments Covered | Procedure, End use |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Companies Mentioned | Allergan; Hologic (cynosure); Johnson & Johnson; Galderma; Lumenis; Solta Medical; Syneron Candela; Alma Laser |
By Procedure Analysis
The injectables segment dominated the market for non-invasive aesthetic treatment and accounted for the largest revenue share of 64.0% in 2021. Injectables can be easily used by surgeons and provide faster treatment with quick results and less downtime as compared to others.
Laser hair removal is fast gaining popularity as it is cost-effective and saves time compared to waxing, shaving, or using hair removal cream. According to the International Society of Aesthetic Plastic Surgery (ISAPS), hair removal was among the top 5 nonsurgical procedures carried out at a global level in 2020.
By End-use Analysis
The medspa segment dominated the market for non-invasive aesthetic treatment accounted for the largest revenue share of 33.9% in 2021. The end-user segment is divided into Hospital/Surgery Center, Medspa, Traditional Spa, HCP owned clinics.
Medspa is a facility where cosmetic services are provided under the supervision of a licensed physician. All noninvasive treatments are performed in these facilities, which include facial injections, non-invasive body contouring, skin rejuvenation, and laser treatments by experienced professionals.
Medspas are increasingly adopting novel treatment systems to cater to a wider esthetic need of patients, therefore the segment is witnessing growth. The employees in Medspas need to have a license in esthetics as well as a medical education.
By Regional Analysis
North America dominated the market for non-invasive aesthetic treatment and held the largest revenue share of 38.4% in 2021 owing to increasing demand for cosmetic procedures by both adults and the geriatric population.
In the Asia Pacific, the market for non-invasive aesthetic treatment is expected to witness the highest CAGR of 16.6% during the forecast period. The region is backed by countries such as China, India, and Thailand.
Read also @ Sacroiliac Joint Fusion Market Size Hit US$ 761.45 Million by 2030
Major Key Players Covered in The Non-invasive Aesthetic Treatment Market Report include
- Hologic, Inc.
- Allergan, Inc.
- Galderma S.A
- Alma Lasers
- Syneron Candela
- Johnson & Johnson
- MerzPharma
- Lumenis
- Solta
- Cutera Inc.
Non-invasive Aesthetic Treatment Market Segmentation
- Procedure Type
- Injectables
- Botulinum Toxin
- Calcium Hydroxylapatite
- Hyaluronic Acid
- Polymer Filler
- Collagen
- Skin Rejuvenation
- Chemical Peel
- Laser Skin Resurfacing
- Photorejuvenation
- Others
- Hair Removal
- Nonsurgical Fat Reduction
- Sclerotherapy
- Cellulite Treatment
- Injectables
- End-use
- Hospital/Surgery Center
- Medspa
- Traditional Spa
- HCP owned clinic
- Regional
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Italy
- Spain
- Asia Pacific
- Japan
- China
- India
- Thailand
- South Korea
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- North America
Table of Contents
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Non-invasive Aesthetic Treatment Market, By Procedure Type
7.1. Non-invasive Aesthetic Treatment Market, by Procedure Type, 2021-2030
7.1.1. Injectables
7.1.1.1. Market Revenue and Forecast (2017-2030)
7.1.2. Skin Rejuvenation
7.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 8. Global Non-invasive Aesthetic Treatment Market, By End-use
8.1. Non-invasive Aesthetic Treatment Market, by End-use, 2021-2030
8.1.1. Hospital/Surgery Center
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Medspa
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Traditional Spa
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. HCP owned clinic
8.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Non-invasive Aesthetic Treatment Market, Regional Estimates and Trend Forecast
9.1. North America
9.1.1. Market Revenue and Forecast, by Procedure Type (2017-2030)
9.1.2. Market Revenue and Forecast, by End-use (2017-2030)
9.1.3. U.S.
9.1.3.1. Market Revenue and Forecast, by Procedure Type (2017-2030)
9.1.3.2. Market Revenue and Forecast, by End-use (2017-2030)
9.1.4. Rest of North America
9.1.4.1. Market Revenue and Forecast, by Procedure Type (2017-2030)
9.1.4.2. Market Revenue and Forecast, by End-use (2017-2030)
9.2. Europe
9.2.1. Market Revenue and Forecast, by Procedure Type (2017-2030)
9.2.2. Market Revenue and Forecast, by End-use (2017-2030)
9.2.3. UK
9.2.3.1. Market Revenue and Forecast, by Procedure Type (2017-2030)
9.2.3.2. Market Revenue and Forecast, by End-use (2017-2030)
9.2.4. Germany
9.2.4.1. Market Revenue and Forecast, by Procedure Type (2017-2030)
9.2.4.2. Market Revenue and Forecast, by End-use (2017-2030)
9.2.5. France
9.2.5.1. Market Revenue and Forecast, by Procedure Type (2017-2030)
9.2.5.2. Market Revenue and Forecast, by End-use (2017-2030)
9.2.6. Rest of Europe
9.2.6.1. Market Revenue and Forecast, by Procedure Type (2017-2030)
9.2.6.2. Market Revenue and Forecast, by End-use (2017-2030)
9.3. APAC
9.3.1. Market Revenue and Forecast, by Procedure Type (2017-2030)
9.3.2. Market Revenue and Forecast, by End-use (2017-2030)
9.3.3. India
9.3.3.1. Market Revenue and Forecast, by Procedure Type (2017-2030)
9.3.3.2. Market Revenue and Forecast, by End-use (2017-2030)
9.3.4. China
9.3.4.1. Market Revenue and Forecast, by Procedure Type (2017-2030)
9.3.4.2. Market Revenue and Forecast, by End-use (2017-2030)
9.3.5. Japan
9.3.5.1. Market Revenue and Forecast, by Procedure Type (2017-2030)
9.3.5.2. Market Revenue and Forecast, by End-use (2017-2030)
9.3.6. Rest of APAC
9.3.6.1. Market Revenue and Forecast, by Procedure Type (2017-2030)
9.3.6.2. Market Revenue and Forecast, by End-use (2017-2030)
9.4. MEA
9.4.1. Market Revenue and Forecast, by Procedure Type (2017-2030)
9.4.2. Market Revenue and Forecast, by End-use (2017-2030)
9.4.3. GCC
9.4.3.1. Market Revenue and Forecast, by Procedure Type (2017-2030)
9.4.3.2. Market Revenue and Forecast, by End-use (2017-2030)
9.4.4. North Africa
9.4.4.1. Market Revenue and Forecast, by Procedure Type (2017-2030)
9.4.4.2. Market Revenue and Forecast, by End-use (2017-2030)
9.4.5. South Africa
9.4.5.1. Market Revenue and Forecast, by Procedure Type (2017-2030)
9.4.5.2. Market Revenue and Forecast, by End-use (2017-2030)
9.4.6. Rest of MEA
9.4.6.1. Market Revenue and Forecast, by Procedure Type (2017-2030)
9.4.6.2. Market Revenue and Forecast, by End-use (2017-2030)
9.5. Latin America
9.5.1. Market Revenue and Forecast, by Procedure Type (2017-2030)
9.5.2. Market Revenue and Forecast, by End-use (2017-2030)
9.5.3. Brazil
9.5.3.1. Market Revenue and Forecast, by Procedure Type (2017-2030)
9.5.3.2. Market Revenue and Forecast, by End-use (2017-2030)
9.5.4. Rest of LATAM
9.5.4.1. Market Revenue and Forecast, by Procedure Type (2017-2030)
9.5.4.2. Market Revenue and Forecast, by End-use (2017-2030)
Chapter 10. Company Profiles
10.1. Hologic, Inc.
10.1.1. Company Overview
10.1.2. Procedure Type Offerings
10.1.3. Financial Performance
10.1.4. Recent Initiatives
10.2. Allergan, Inc.
10.2.1. Company Overview
10.2.2. Procedure Type Offerings
10.2.3. Financial Performance
10.2.4. Recent Initiatives
10.3. Galderma S.A
10.3.1. Company Overview
10.3.2. Procedure Type Offerings
10.3.3. Financial Performance
10.3.4. Recent Initiatives
10.4. Alma Lasers
10.4.1. Company Overview
10.4.2. Procedure Type Offerings
10.4.3. Financial Performance
10.4.4. Recent Initiatives
10.5. Syneron Candela
10.5.1. Company Overview
10.5.2. Procedure Type Offerings
10.5.3. Financial Performance
10.5.4. Recent Initiatives
10.6. Johnson & Johnson
10.6.1. Company Overview
10.6.2. Procedure Type Offerings
10.6.3. Financial Performance
10.6.4. Recent Initiatives
10.7. MerzPharma
10.7.1. Company Overview
10.7.2. Procedure Type Offerings
10.7.3. Financial Performance
10.7.4. Recent Initiatives
10.8. Lumenis
10.8.1. Company Overview
10.8.2. Procedure Type Offerings
10.8.3. Financial Performance
10.8.4. Recent Initiatives
10.9. Solta
10.9.1. Company Overview
10.9.2. Procedure Type Offerings
10.9.3. Financial Performance
10.9.4. Recent Initiatives
10.10. Cutera Inc.
10.10.1. Company Overview
10.10.2. Procedure Type Offerings
10.10.3. Financial Performance
10.10.4. Recent Initiatives
Chapter 11. Research Methodology
11.1. Primary Research
11.2. Secondary Research
11.3. Assumptions
Chapter 12. Appendix
12.1. About Us
Glossary of Terms
Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/39012
Contact Us:
Vision Research Reports
Call: +1 9197 992 333
